Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III; Corresponding Change to Permit Requirements
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register PolicyResearchSafetyTHCIndustryDosingPain Why This Matters I need the…
Schedules of Controlled Substances: Rescheduling of Food and Drug Administration Approved Products Containing Marijuana From Schedule I to Schedule III; Corresponding Change to Permit Requirements
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register PolicyResearchSafetyIndustry Why This Matters This rescheduling from…
What the 2026 DOJ Rescheduling Order Means in Practice
On April 23, 2026, the U.S. DOJ moved state-licensed medical cannabis to Schedule III, the first federal acknowledgment of accepted medical value in 55 years. Dr. Caplan breaks down what actually changed for patients, physicians, and the research…
Characterizing public comments via Regulations.gov in response to proposed cannabis rescheduling in the United States.
The United States Drug Enforcement Administration's (DEA) proposed rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances A...
CED Regulatory Digest, Since Last Digest, 1 items
Digest covering 1 recent regulatory items.
Characterizing public comments via Regulations.gov in response to proposed cannabis rescheduling in the United States.
The United States Drug Enforcement Administration's (DEA) proposed rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances A...
Tennessee Lawmakers Aim to Take Cannabis Rescheduling Out of Expert Hands, Reserve …
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic PolicyMedical AuthorityPatient…
Cannabis rescheduling testimony in Congress (Newsletter: April 7, 2026)
✦ New CED Clinical Relevance #55 Clinical Context Background information relevant to the evolving cannabis medicine landscape. PolicyResearchMental Health Clinical Summary A former Indiana attorney general has publicly opposed Governor Mike…
Marijuana Rescheduling Countdown: Why the "Order of Operations" and Todd Blanche’s …
✦ New CED Clinical Relevance #62 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyResearchSafetyIndustry Why This Matters Rescheduling cannabis could accelerate clinical trial timelines by removing…
Cannabis rescheduling testimony in Congress (Newsletter: April 7, 2026)
✦ New CED Clinical Relevance #70Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic PolicyFederal RegulationMedical…